BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 5,044,847 shares of Opus Genetics Inc. common stock as of September 30, 2026, representing 6.1% of the class.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 5,044,847 shares of Opus Genetics Inc. common stock.
  • Percent of class: The filing discloses that the 5,044,847 shares represent 6.1% of the outstanding class.
  • Sole voting power: BlackRock reported sole power to vote or direct the vote of 4,961,536 shares.
  • Sole dispositive power: BlackRock reported sole power to dispose or direct the disposition of 5,044,847 shares.
  • No shared voting or dispositive power: Shared voting power and shared dispositive power are each reported as 0.
  • Triggering date: The date of the event requiring this filing is stated as September 30, 2026.
  • Filer classification: BlackRock is identified as a parent holding company (type "HC"), incorporated in Delaware, with its principal office at 50 Hudson Yards, New York, NY 10001.

BlackRock's Schedule 13G Filing on Opus Genetics Common Stock

According to the Schedule 13G filed October 27, 2026, BlackRock, Inc. disclosed that it beneficially owned 5,044,847 shares of common stock of Opus Genetics Inc. (CUSIP 67577R102) as of September 30, 2026. The filing states this position represents 6.1% of the outstanding class. Opus Genetics Inc. is headquartered at 8 Davis Drive, Durham, NC 27713, according to the filing.

The filing indicates that BlackRock holds sole voting power over 4,961,536 shares and sole dispositive power over all 5,044,847 shares reported. Shared voting power and shared dispositive power are each listed as 0. BlackRock is classified in the filing as a parent holding company (type "HC") organized in Delaware. The filing notes, consistent with SEC Release No. 34-39538 (January 12, 1998), that the schedule "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and that it "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release."

With respect to dividends and sale proceeds, the filing discloses that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of OPUS GENETICS INC," and further states that "no one person's interest in the common stock of OPUS GENETICS INC is more than five percent of the total outstanding common shares." The subsidiary or subsidiaries through which the securities are held are identified in Exhibit 99 attached to the filing. The statement was signed by Spencer Fleming, Managing Director of BlackRock, Inc., on October 27, 2026.

What Was Disclosed

BlackRock, Inc. filed a Schedule 13G reporting beneficial ownership of 5,044,847 shares, or 6.1%, of Opus Genetics Inc. common stock as of September 30, 2026, with sole voting power over 4,961,536 shares and sole dispositive power over all reported shares.